Gene-editing technology CRISPR is projected to have a fast revenue growth over the next five years, as revenues grow from $779 million in 2017 to $5.2 billion in 2023.
Altering the genome, typically to better understand gene and protein function. This also paves the way for gene therapy.
Last year, a scientific journal challenged just how “revolutionary” CRISPR was, claiming that it caused unintended gene mutations. But, a recent study proves how this was simply all just an over exaggeration.
DNA twitches during transcription to bring distant regions in contact and enhance gene expression, according to Stanford researchers, who devised a new way to label individual, nonrepetitive DNA sequences.
Scientists have tweaked the DNA in human heart cells to correct mutations that cause a deadly disease, which if proved safe could eventually cure children of Duchenne Muscular Dystrophy (DMD).
A new animal study involving virally-delivered gene therapies has indicated that high treatment doses might not be as safe as previous human trials have suggested
Researchers have made new inroads into understanding germ cell tumours, a diverse and rare group of cancers that begin in germ cells — the cells that develop into sperm and eggs.
A systematic study uncovering multiple new and unusual bacterial immune defence mechanisms could pave the way toward new biotech tools.
To help you plan your visit, or perhaps inspire you to sign up for your free place, we’ve put together a handy guide to this year’s theme, and some of our top picks from the agenda.
The National Institutes of Health have announced that it will launch an effort to remove barriers from the adoption of genome editing for treating patients.